abiraterone

Abiraterone (CB-7598) (CB-7598) is an effective steroidal cytochrome P450 17alpha-hydroxylase-17, 20-lyase (CYP17) inhibitor (IC50: 4 nM).

Abiraterone Acetate (CB7630) is an androstene derivative that inhibits STEROID 17-ALPHA-HYDROXYLASE and is used as an ANTINEOPLASTIC AGENT in the treatment of metastatic castration-resistant PROSTATE CANCER.

Abiraterone Metabolite 1, a 5β-reduced derivative of abiraterone, acts by inhibiting CYP17A1, thereby blocking androgen synthesis and extending survival in prostate cancer patients.

D4-abiraterone is the active metabolite of abiraterone produced by 3β-HSD and is further metabolised by SRD5A.Δ4-Abiraterone is an inhibitor of CYP17A1, 3β-HSD and SRD5A, and an antagonist of the androgen receptor.

Abiraterone decanoate is a prodrug of Abiraterone that provides controlled release and prolonged inhibition of the enzyme CYP17 through intramuscular (IM) administration, the sustained inhibition ability of Abiraterone decanoate attrack interest in researches of cancer.

Abiraterone sulfate, a metabolite of Abiraterone, is a potent and irreversible CYP17A1 inhibitor with antiandrogen activity [1].

Abiraterone N-oxide, a metabolite of Abiraterone, serves as a potent and irreversible CYP17A1 inhibitor with antiandrogen activity [1].

Abiraterone sulfate N-oxide, a carboxylic acid and major metabolite of Abiraterone, is utilized in prostate cancer research [1] [2].

Anhydro abiraterone is a degradation product of Abiraterone acetate. Abiraterone acetate (CB7630) is an orally active, selective, and irreversible inhibitor of CYP17A1, possessing antiandrogen activity.

5,6-Dihydroabiraterone, a metabolic derivative of Abiraterone, is a potent and irreversible inhibitor of CYP17A1, exhibiting antiandrogen and antitumor activities, particularly effective against castration-resistant prostate cancer (CRPC) [1] [2].